Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates

Annals of Oncology

Volumn 16, Issue 8, 2005, Pages 1311-1319

  Folprecht, G ^a   Grothey, A ^b   Alberts, S ^b   Raab, H R ^c   Kohne C H ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b MAYO CLINIC   (United States)

^c KLINIKUM OLDENBURG   (Germany)

Author keywords

Colorectal cancer; Liver metastases; Neoadjuvant chemotherapy; Resection

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; PIRARUBICIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CORRELATION ANALYSIS; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LIVER SURGERY; PREDICTION; PREOPERATIVE CARE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 23844448040     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi246     Document Type: Article

References (63)

1. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99.
2. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
3. Scheele J, Stang R, Altendorf Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
4. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.
5. Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-1262.
6. Adam R. Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14 (Suppl 2): Ii13-ii16.
7. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16: 301-308.
8. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10: 896-903.
9. Piedbois P, Michiels S. Meta-Analysis Group in Cancer. Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: An updated meta-analysis based on 2,751 patients. Proc Am Soc Clin Oncol 2003; 22: 294.
10. Köhne CH, Van Cutsem E, Wils JA et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol 2003; 22: 254.
11. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
12. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
13. Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21: 129a.
14. Tournigand C, Andre T, Achille E et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. J Clin Oncol 2004; 22: 229-237.
15. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of Fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
16. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
17. Cals L, Rixe O, Francois E et al. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol 2004; 15: 1018-1024.
18. Roth AD, Seium Y, Ruhstaller T et al. Oxaliplatine (OXA) combined with irinotecan (CPT-11) and 5FU/leucovorin (OCFL) in metastatic colorectal cancer (MCRC): A phase I-II study. Proc Am Soc Clin Oncol 2002; 21: 143a.
19. Quenet F, Nordlinger B, Rivoire M et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial. Proc Am Soc Clin Oncol 2004; 23: (Abstr 3613).
20. Souglakos J, Ziras N, Polyzos A et al. Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): Preliminary results of a multicenter randomized phase III trial. Proc Am Soc Clin Oncol 2004; 23: (Abstr 3532).
21. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
22. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
23. Lenz H-J, Mayer RJ, Gold PJ et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 2004; 23: (Abstr 3510).
24. Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-C225) Plus Irinotecan (CPT-11) is Active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermal Growth Factor Receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: 3a.
25. Tabernero J, Van Cutsem E, Sastre J et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/ folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. Proc Am Soc Clin Oncol 2004; 23: (Abstr 3512).
26. Rougier P, Raoul JL, Van Laethem JL et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol 2004; 23: (Abstr 3513).
27. Lutz MP, Schöffski P, Folprecht G et al. A phase I/II study of cetuximab (C225) plus irinotecan (CPT-11) and 24 h infusional 5FU/ folinic acid (FA) in the treatment of metastatic colorectal cancer (MCRC) expressing the epidermal growth factor receptor (EGFR). Ann Oncol 2002; 13: 73.
28. Rosenberg AH, Loehrer PJ, Needle M et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002; 21: 135a.
29. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
30. Fowler WC, Eisenberg BL, Hoffman JP. Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma. J Surg Oncol 1992; 51: 122-125.
31. Figueras J, Valls C, Rafecas A et al. Resection rate and effect of post-operative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88: 980-985.
32. Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-939.
33. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
34. de la Camara J, Rodriguez J, Rotellar F et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 2004; 23: (Abstr 3593).
35. Rivoire M, De Cian F, Meeus P et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002; 95: 2283-2292.
36. Ho WM, Mok TSK, Ma BB et al. Liver resection after irinotecan (CPT-11), 5-fluorouracil (5FU) and folinic acid (FA) for patients (pts) with unresectable liver metastases (Mets) from colorectal cancer (CRC). Proc Am Soc Clin Oncol 2003; 22: 312.
37. Meric F, Patt YZ, Curley SA et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000; 7: 490-495.
38. Leonard GS, Fong Y, Jarnagin W et al. Liver resection after hepatic infusion (HAI) plus systemic oxalipatin (OXAL) combination in pretreated patients with extensive unresectable colorectal liver metastases. Proc Am Soc Clin Oncol 2004; 23: (Abstr 3542).
39. Shankar A, Leonard P, Renaut AJ et al. Neo-adjuvant therapy improves resectability rates for colorectal liver metastases. Ann R Coll Surg Engl 2001; 83: 85-88.
40. Akasu T, Moriya Y, Takayama T. A pilot study of multimodality therapy for initially unresectable liver metastases from colorectal carcinoma: hepatic resection after hepatic arterial infusion chemotherapy and portal embolization. Jpn J Clin Oncol 1997; 27: 331-335.
41. Miyanari N, Mori T, Takahashi K, Yasuno M. Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer. Dis Colon Rectum 2002; 45: 1503-1509.
42. Alberts SR, Donohue JH, Mahoney MR et al. Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study. Proc Am Soc Clin Oncol 2003; 22: 263.
43. Zelek L, Bugat R, Cherqui D et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol 2003; 14: 1537-1542.
44. Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-520.
45. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004; 240: 644-657.
46. Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-939.
47. Gil-Delgado MA, Guinet F, Castaing D et al. Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. Am J Clin Oncol 2001; 24: 101-105.
48. Folprecht G, Lutz M, Schöffski P et al. Cetuximab/irinotecan/ high-dose-5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). Proc Gastrointest Canc Symp (ASCO/AGA/ASTRO/SSO) 2004; 1: (Abstr 283).
49. Wein A, Riedel C, Kockerling F et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 2001; 12: 1721-1727.
50. Falcone A, Masi G, Allegrini G et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20: 4006-4014.
51. Falcone A, Masi G, Cupini S et al. Surgical resection of metastases (mts) after biweekly chemotherapy with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI) in initially unresectable metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2004; 23: (Abstr 3553).
52. Fisher GA, Kuo T, Cho CD et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004; 23: (Abstr 3514).
53. Gruenberger T, Schuell B, Kornek G, Scheithauer W. Neoadjuvant chemotherapy for resectable colorectal cancer liver metastases: Impact on magnitude of liver resection and survival. Proc Am Soc Clin Oncol 2004; 23: (Abstr 3598).
54. Adam R, Pascal G, Castaing D et al. Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061.
55. Köhne CH, Cunningham D, Di Costanzo F et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
56. Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004; 15: 1453-1459.
57. Elias D, Youssef O, Sideris L et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004; 86: 4-9.
58. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317-319.
59. Scappaticci F, Fehrenbacher L, Cartwright T et al. Analysis of wound healing and bleeding post-surgery in metastatic colorectal cancer patients treated with bevacizumab. Proc Gastrointest Canc Symp (ASCO/AGA/ ASTRO/SSO) 2004; 1: (Abstr 235).
60. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
61. Delaunoit TP, Krook J, Sargent DJ et al. Chemotherapy-allowed resection of metastatic colorectal cancer: A cooperative group experience. Proc Gastrointest Canc Symp (ASCO/AGA/ASTRO/SSO) 2004; 1: 138.
62. Giacchetti S, Bjarnason GA, Garufi C et al. First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer: 4-day chronomodulated (FFL4-10) versus 2-day FOLFOX2. A multicenter randomized Phase III trial of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC 05963). Proc Am Soc Clin Oncol 2004; 23: (Abstr 3526).
63. de Gramont A, Cervantes A, Andre T et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2004; 23: (Abstr 3525).